Early treatment decisions with interferon-alfa therapy in early chronic- phase chronic myelogenous leukemia

Journal of Clinical Oncology

Volumn 16, Issue 3, 1998, Pages 882-889

  Sacchi, Stefano ^a   Kantarjian, Hagop M ^a   Smith, Terry L ^a   O'Brien, Susan ^a   Pierce, Sherry ^a   Kornblau, Steven ^a   Beran, Miloslav ^a   Keating, Michael J ^a   Talpaz, Moshe ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTARABINE;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; PATIENT SELECTION; PHILADELPHIA 1 CHROMOSOME; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; SPLENOMEGALY; STEM CELL TRANSPLANTATION; THROMBOCYTOSIS; TREATMENT OUTCOME;

EID: 0031934751     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.3.882     Document Type: Article

References (18)

1. Kantarjian HM, O'Brien S, Anderlini P, et al: Treatment of chronic myelogenous leukemia: current status and investigational options. Blood 87:3069-3081, 1996
2. Giralt S, Kantarjian HM, Talpaz M: The natural history of chronic myelogenous leukemia in the interferon era. Semin Hematol 32:152-158, 1995
3. Ferrajoli A, Fizzotti M, Liberati AM, et al: Chronic myelogenous leukemia: an update on the biological findings and therapeutic approaches. Crit Rev Oncol Hematol 22:151-174, 1996
4. Kantarjian HM, Smith TL, O'Brien S, et al: Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 122:254-261, 1995
5. Tura S, Baccarani M, Zuffa E: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820-825, 1994
6. Allan N, Richards S, Shepard P, et al: UK Medical Research Council randomized, multicentre trial of interferon-αn1 for chronic myeloid leukemia: Improved survival irrespective of cytogenetic response. Lancet 345:1392-1397, 1995
7. Ohnishi K, Ohno R, Tomonaga M, et al: A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86:906-916, 1995
8. Sacchi S, Kantarjian HM, O'Brien S, et al: Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 13:2401-2407, 1995
9. National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
10. Talpaz M, Kantarjian HM, McCredie KB, et al: Hematologic remission and cytogenetic improvement induced by recombinant human interferon α-A in chronic myelogenous leukemia. N Engl J Med 314:1065-1069, 1986
11. Sokal JE, Cox EB, Baccarani M, Tura S, et al: Prognostic discrimination in good-risk chronic granulocytic leukemia. Blood 63:789-799, 1984
12. Kantarjian HM, Smith T, McCredie KB, et al: Chronic myelogenous leukemia: a multivariate analysis of the associations of patients characteristics and therapy with survival. Blood 66:1326-1335, 1985
13. Kantarjian HM, Keating MJ, Smith T, et al: Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med 88:1-8, 1990
14. Giralt SA, Kantarjian HM, Talpaz M, et al: Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol 11:1055-1061, 1993
15. Shepherd P, Richards S, Allan N: Survival after allogeneic bone marrow transplantation in patients randomized into a trial of IFN-α versus chemotherapy: No significant adverse effect of prolonged IFN-α administration. Blood 86:94a, 1995 (suppl 1)
16. Horowitz MM, Giralt S, Szydlo R, et al: Effect of prior interferon therapy on outcome of HLA-identical sibling bone marrow transplants for chronic myelogenous leukemia in first chronic phase. Blood 88:682a, 1996 (suppl 1)
17. Hehlmann R, Kolb HJ, Berger U: Influence of pretransplant treatment on survival after allogenous bone marrow transplantation in CML. Blood 90:228a, 1997 (suppl 1)
18. Zuffa E, Bandini G, Bonini A, et al: Outcome of allogeneic transplant in CML patients previously treated with alpha-interferon. Analysis in a single institution. Bone Marrow Transplant 15:18, 1995 (suppl 2)